BRIEF-IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA

Reuters
25 Nov 2024

Nov 25 (Reuters) - Imunon Inc :

* IMUNON ANNOUNCES RESULTS FROM ITS END-OF-PHASE 2 MEETING WITH THE FDA FOR ITS LEAD IMNN-001 CLINICAL PROGRAM IN ADVANCED OVARIAN CANCER

* IMUNON INC - IMNN-001 TREATMENT WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS

* IMUNON INC - TO INITIATE 500-PATIENT PHASE 3 TRIAL IN Q1 2025

* IMUNON INC - ANNOUNCES FDA SUPPORT FOR PHASE 3 STUDY OF IMNN-001

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10